Healthy, Hepatic Insufficiency
Conditions
Brief summary
The primary objective of this trial is the evaluation of safety and tolerability in patients with mild to moderate hepatic impairment \[Child-Turcotte-Pugh (CTP) classification A and B\] over different dose regimes of BI 685509 compared to placebo. A secondary objective is to investigate pharmacokinetics of different doses of BI 685509 in patients with mild to moderate hepatic impairment (CTP A and CTP B). In addition, another secondary objective is to compare safety, tolerability, and pharmacokinetics in patients with mild to moderate hepatic impairment (CTP A and CTP B) of single BI 685509 dose to individually matched healthy volunteers
Interventions
DRUGBI 685509
Tablet
DRUGPlacebo
Tablet
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria for all trial participants: * Age ≥ 18 years at Screening * Male or female. Women of childbearing potential (WOCBP) participants and male participants able to father a child must be ready and able to use a highly effective method of birth control per ICH M3 (R2) that results in a low failure rate of less than 1% per year when used consistently and correctly throughout the Trial * Mean Arterial Pressure (MAP) ≥ 85 mmHg at screening visit * Estimated Glomerular Filtration rate (eGFR) \> 70 mL/min/1.73m² according to the CKD-EPI formula at screening visit * Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial Key inclusion for Patient Groups 1 and 2 * If on treatment with non-selective beta blockers (NSBB), stable dose since ≥ 8 weeks prior to screening, with no planned dose change of the therapy during study conduct. All other medications stable 4 weeks prior to screening. * Patient Group 1: Patients with CTP A and portal hypertension (defined as liver stiffness \>15 kPa during screening) and without a previous decompensation event \[ascites, variceal hemorrhage, encephalopathy, or jaundice (except Gilbert's disease or hemolysis when bilirubin will be almost exclusively indirect hyperbilirubinemia)\]. Self-limited and resolved historical events of decompensation like ascites or encephalopathy are allowed if they have occurred at least 6 weeks prior to screening and do not require continued therapeutic intervention at the time of screening. * Patient Group 2: Patients with CTP B (with liver stiffness \>15 kPa during screening) Key inclusion for Healthy Volunteer group * Subjects who are healthy, according to the investigator's assessment, individually matched to a participant among Patient Groups 1 and 2 according to the following criteria: age within ± 5 years, body weight within ± 15%, and gender * Further inclusion criteria apply Key exclusion for all trial participants * Ongoing chronic alcohol or drug use, which in the investigator's opinion, makes the patient an unreliable trial participant or unlikely to complete the trial. * History of relevant orthostatic hypotension, fainting spells, or blackouts based on the investigator´s judgment Key exclusion for Patient Groups * Patient Group 2: treatment-refractory ascites * Patient Group 2: recent decompensation event (refractory ascites, recurrent variceal hemorrhage, recurrent hepatic encephalopathy, spontaneous bacterial peritonitis or hepatorenal syndrome) within 6 weeks of screening * Further
Exclusion criteria
apply
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of subjects with drug-related Adverse Events (AEs) among different dose regimes over each up-titration | Up to day 28 |
Secondary
| Measure | Time frame |
|---|---|
| Cmax (maximum measured concentration of the analyte in plasma) | Up to 72 hours |
| AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) [AUCτ,ss will be AUC0-12,ss for bid dosing] | Up to 72 hours |
| Cmax,ss (maximum measured concentration of the analyte in plasma at steady) | Up to 72 hours |
| AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to time of the last quantifiable data point) | Baseline and Up to 72 hours |
| Change from baseline in seated diastolic blood pressure (DBP) | Baseline and Up to 28 days |
| Change from baseline in heart rate (HR) | Baseline and Up to 28 days |
| Change from baseline in body weight | Baseline and Up to 28 days |
| Change from baseline in seated systolic blood pressure (SBP) | Baseline and Up to 28 days |
Countries
United States
Outcome results
None listed